AI Solutions
Radiotherapy
- Radiation Oncology
Represented by Human Bytes in the Nordics and Benelux, TheraPanacea’s zero-click AI automation platform for high-precision radiotherapy is in clinical use in 150+ departments in Europe and world-wide with up to +90% time saving for dosimetrists, RTTs and radiation oncologists.
ART-Plan™ is a web-browser based, scalable and modular AI automation platform for radiotherapy. Current modules include:
Annotate™: AI-powered software that provides fully automatic delineation of 200+ CT and MRI-based organs at risk (OARs) and lymph nodes from Simulator-to-TPS within 2-3 minutes and with comparable accuracy as clinical experts, utilizing latest consensus contouring guidelines.
MR-Box™: Generates MRI-based pseudo-CT (conventional MRIs and MR linacs) for MR-only and MR guided radiotherapy to avoid registration errors, cost saving and improved patient comfort. Compatible with Annotate for auto-contouring of OARs & lymph nodes on MRI scans.
SmartFuse™: The first AI-powered software for high-precision rigid and elastic fusion, that includes the management of 4D-CT and a real-time deformation of contours for faster replanning.
AdaptBox™ : Provides decision making support using customisable objective metrics for adaptive radiotherapy by utilizing AI to generate an enhanced and augmented pseudo-CT from CBCT with a CT-like FOV, expert like contours using AI auto-contouring as well as re-calculating and comparing dose metrics to the active treatment plan.
IT deployment: The ART-Plan AI automation platform is web-browser based and can be deployed via cloud or locally as per IT preference.
“Today, the AI-based software from Therapanacea is part of the daily routine of medical physicists and radiation oncologists. It is used at the DTZ to display all anatomies for all CT scans. The contours hardly need to be adjusted. Installation was remarkably easy and ready to process scans of our patients straight away”
“ART-Plan™ has achieved a high level of acceptance among the various teams in our department. It saves a lot of valuable time that is better spent on interdisciplinary discussions and complex planning tasks”
We often see implementation of AI being overcomplicated, leading to massive delays in lifting stresses on departments, staff and patient care:
- Insisting on perfect guideline compliance from the start: When assessing AI auto-contouring as an example, departments sometimes compare meticulously contoured “perfect” datasets to the AI, at times with overrepresentation of edge cases. Based on departments who successfully and rapidly implemented AI, we propose their practice of comparing the AI to daily routine clinical contours. The goal is to work towards guideline compliance over time while considering excessive cost of reaching from great to “perfect”, in consideration guidelines evolving too.
- Creating vendor monopoly: Radiotherapy is dominated by a few large vendors, typically bundling in check-the-box AI solutions. This creates high risk for vendor lock-in and we see this negatively impacting departments on various levels:
- It decreases their procurement power thus increasing cost to the department.
- While the initial solution is based on “AI” and “cheap”, it may not provide tangible benefits (e.g. time savings)
- It can make the vendors “lazy” in providing improvements
- We propose an annual subscription model which puts us and our partner vendor “on our toes”. We have to continuously deliver quality to you to keep us as your preferred partner. By implementing zero-click radiotherapy workflows that deploy and integrate seamlessly in the background with existing TPS systems. As a result, you always have the best solution(s) and the most competitive cost
- Introducing in-house developed AI that is already commercial (regulatory liability): R&D is vital but much more efficient if its end-goal concentrates on providing tools that aren’t commercially available yet (e.g. target auto-contouring) or when existing tools aren’t widely clinically proven in providing massive benefits. In addition, with the introduction of MDR, in-house developed software easily becomes a regulatory liability to the department and hospital. Where there are commercially available alternatives, MDR certification and post-market surveillance are a must which include extensive processes, a quality management system, and high costs. Applying an exception to MDR is not possible in this case, according to the new regulation.
Clinical evidence
https://www.therapanacea.eu/resources/publications/
TheraPanacea is a serial award-winning medical technology company founded in 2017 harnessing AI to develop cutting-edge software for more efficient and precise cancer care. Their radiotherapy AI automation platform ART-Plan™ has been CE-marked in 2019 (FDA clearance, etc. followed soon) and since then ART-Plan is already in use across Europe and US.
- In use in over 150 radiotherapy departments across Europe and world-wide.
- 1 out of 4 radiotherapy patients in France is being auto-contoured with TheraPanacea’s ART-Plan
- 150,000 patient cases are being auto-contoured per year with ART-Plan world-wide